Crohn’s disease

Treatment

Mild disease may be treated by mesalazine or no treatment with limited number of courses of topical steroids.

The gold standard of care for moderate to severe Crohn’s disease is the Combo therapy, the uninterrupted combination of anti-TNFα monoclonal antibodies and immunosuppressant. However, this kind of treatment raises safety and costs issues.
Indeed, anti-TNFα is the most expensive medication and potential adverse effects are associated with the Combo therapy, namely cancers and possible increase of severe infections. In addition, patients are exposed to class-specific drug complications.

Description of the disease

Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) affecting the gastro-intestinal tract. CD often begins at young age and lasts the whole life. The prevalence is 20-30% higher for women than for men.

CD is characterized by a sequence of active disease episodes (flare-ups) and remissions of variable duration. The chronicity of CD has a significant impact on patients’ quality of life (QoL).

Genetic susceptibility, modified composition of the gut microbiota and impaired function of the mucosal immune system are the main known contributors to the etiology of CD. However, the primary cause remains unknown.

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.


We track anonymized user information to improve our website.
  • _ga 2 year
  • _gid 24 hours
  • _gat 1 minute
  • AMP_TOKEN 30 seconds to 1 year
  • _gac_ 90 days

Decline all Services
Accept all Services